

Faculty

Joan Albanell

Hospital del Mar (IMIM)

Luis Álvarez-Vallina

Hospital 12 de Octubre

Guillem Arguiles

Vall d'Hebron Inst. d'Oncologia (VHIO)

Edurne Arriola

Hospital del Mar (IMIM)

Joaquim Bellmunt

Associate Professor, Harvard Medical School
IMIM Senior Researcher. Cancer Research Program.

Beatriz Bellosillo

Hospital del Mar (IMIM)

Sonia Guedan

IDIBAPS/ Hospital Clínic

Hans Hammers

UT Southwestern Medical Center

Núria Juanpere

Hospital del Mar (IMIM)

Núria López-Bigas

IRB Barcelona

Pablo Maroto

Hospital de la Santa Creu i Sant Pau

Juan Martín Liberal

Institut Català d'Oncologia (ICO)

Clara Montagut

Hospital del Mar (IMIM)

Ernest Nadal

Institut Català d'Oncologia (ICO)

Júlia Perera

Hospital del Mar (IMIM)

Josep Ma Piulats

Institut Català d'Oncologia (ICO)

Alejo Rodríguez-Vida

Hospital del Mar (IMIM)

Ana Vivancos

Vall d'Hebron Inst. d'Oncologia (VHIO)

IMIM

Parc
de Salut
MAR
Barcelona

Institut Hospital del Mar
d'Investigacions Mèdiques

30th
October
2019

With the collaboration of



Bristol-Myers Squibb



AstraZeneca



MSD

TECHNICAL SECRETARIAT



Aula Campus MAR

Aula Campus MAR
A/A Fernando Ochoa

T. 934 703 513
fochoa@meetingpharma.com
www.meetingpharma.com



Under the scientific backing

SEOM

Sociedad Española
de Oncología Médica

SEOM® es una marca registrada.
El aval de SEOM no implica la
organización ni financiación del evento

With the endorsement of



Organized by the IMIM Foundation


Optimizing Immunotherapy

New Approaches, Biomarkers,
Sequences and Combinations

Symposium Director: Dr. Joaquim Bellmunt.

Associate Professor, Harvard Medical School
IMIM Senior Researcher. Cancer Research Program.

PRBB Auditorium, Barcelona
C/ Dr. Aiguader, 88 - 08003 Barcelona



30th
October
2019

Optimizing Immunotherapy

New Approaches, Biomarkers,
Sequences and Combinations

08:30 - 09:00

Registration

09:00 - 09:05

Welcome and opening. *Joaquim Bellmunt*

09:05 - 09:30

Combination immunotherapy: Challenges and Future Trends.
Luis Álvarez-Vallina

09:30 - 11:00

TABLE 1. Immunotherapy in the clinic, focused on long term survival.

Moderator: *Alejo Rodríguez-Vida*

09:30 - 09:45

Melanoma. *Clara Montagut*

09:50 - 10:05

Lung. *Ernest Nadal*

10:10 - 10:25

Genitourinary. *Pablo Maroto*

10:25 - 10:40

Other IO indications. *Juan Martín Liberal*

10:40 - 11:00

Discussion

11:00 - 11:20



11:20 - 13:40

TABLE 2. Biomarkers in immunotherapy.

Moderator: *Joan Albanell*

11:20 - 11:35

PDL1 as a predictive biomarkers: pros and cons. *Núria Juanpere*

11:40 - 11:55

Predictive value of the Mutational load, neoantigens and clonal antigens.
Somatic and germline genomic alterations. *Ana Vivancos*

12:00 - 12:15

RNA Signatures as predictive biomarker. *Júlia Perera*

12:20 - 12:35

Microbiome as predictor of benefit and toxicity. *Guillem Arguiles*

12:40 - 12:55

How to analyze genomic data for immunotherapy appliances. *Núria López-Bigas*

13:00 - 13:15

TMB. Blood based biomarkers. Liquid biopsy. *Beatriz Bellosillo*

13:20 - 13:40

Discussion

13:40 - 14:30



14:30 - 16:40

TABLE 3. Futures perspectives on immunotherapy.

Moderator: *Eduarne Arriola*

14:30 - 14:45

Combination and sequencing: with radiation therapy, with chemotherapy
and with targeted therapies. *Josep Ma Piulats*

14:50 - 15:05

CAR T-cells. *Sonia Guedan*

15:10 - 15:30

Discussion

15:35 - 15:50

New biomarkers in the IO era. *Joaquim Bellmunt*

15:55 - 16:30

First line treatment of RCC. *Hans Hammers*

16:30

Closing remarks. *Joaquim Bellmunt*